Morgan Stanley’s Scopus BioPharma Inc. Common Stock SCPS Stock Holding History

Morgan Stanley’s Portfolio SCPS Stock Details SCPS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-2	Closed	–	–	8053
2022 Q3	$0	Buy	+2	New	+$1	﹤0.01%	8077
2022 Q2	–	Sell	-2,109	Closed	-$1K	–	8178
2022 Q1	$1K	Sell	2,109 -41,903	-95%	-$40.4K	﹤0.01%	7918
2021 Q4	$72K	Buy	44,012 +43,012	+4,301%	+$130K	﹤0.01%	6627
2021 Q3	$4K	Sell	1,000 -612	-38%	-$3.15K	﹤0.01%	7572
2021 Q2	$11K	Buy	1,612 +655	+68%	+$4.66K	﹤0.01%	7214
2021 Q1	$8K	Buy	+957	New	+$10K	﹤0.01%	7019

Other funds holding SCPS

MRCM

M&R Capital Management Summit, New Jersey $454M AUM 40.11% 1-Year Est. Return

Morgan Stanley's SCPS Position: Q4 2022 in Review

Morgan Stanley sold out of Scopus BioPharma Inc. Common Stock (SCPS) in Q4 2022, closing a stake of 2 shares.

Morgan Stanley first reported a position in SCPS in Q1 2021 and held it in 6 quarters. The position peaked at $72K in Q4 2021. 1 fund tracked by Wall St. Rank holds SCPS as of Q4 2022.

Morgan Stanley reported no remaining Scopus BioPharma Inc. Common Stock position as of Q4 2022 after selling out during the quarter.
Morgan Stanley sold 2 Scopus BioPharma Inc. Common Stock shares in Q4 2022.
Morgan Stanley first reported a position in Scopus BioPharma Inc. Common Stock in Q1 2021 and held it in 6 quarters.
Morgan Stanley's Scopus BioPharma Inc. Common Stock position peaked at $72K in Q4 2021.
1 fund tracked by Wall St. Rank held Scopus BioPharma Inc. Common Stock as of Q4 2022.

Based on Morgan Stanley's 13F filing for Q4 2022, filed 14 Feb 2023.